Co-Authors
This is a "connection" page, showing publications co-authored by RICHARD E CHAMPLIN and JEFFREY J MOLLDREM.
Connection Strength
1.308
-
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2017 03; 31(3):697-704.
Score: 0.148
-
Bacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease. Res Sq. 2023 Jan 31.
Score: 0.057
-
Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Williston Park). 2003 Jan; 17(1):94-100; discussion 103-7.
Score: 0.057
-
Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med. 2022 11 16; 14(671):eabo3445.
Score: 0.057
-
Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell. 2022 09 29; 185(20):3705-3719.e14.
Score: 0.056
-
Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002 Sep; 30(6):367-73.
Score: 0.056
-
Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2001 May; 27 Suppl 2:S13-22.
Score: 0.051
-
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021 08 20; 39(24):2710-2719.
Score: 0.051
-
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Feb 01; 97(3):631-7.
Score: 0.050
-
Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000 Oct; 111(1):18-29.
Score: 0.049
-
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000 Sep; 6(9):1018-23.
Score: 0.049
-
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant. 2000 Jun; 25(11):1137-40.
Score: 0.048
-
Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol Oncol Clin North Am. 1999 Oct; 13(5):1041-57, vii-viii.
Score: 0.046
-
A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 1999 Jun 01; 59(11):2675-81.
Score: 0.045
-
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica. 2019 12; 104(12):e555-e557.
Score: 0.044
-
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ? Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biol Blood Marrow Transplant. 2019 07; 25(7):1347-1354.
Score: 0.044
-
Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol. 1999 Mar; 11(2):87-95.
Score: 0.044
-
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 2016 07 14; 128(2):297-312.
Score: 0.036
-
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92.
Score: 0.033
-
Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014 Sep 25; 124(13):2034-45.
Score: 0.032
-
Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012 Dec 13; 367(24):2305-15.
Score: 0.028
-
Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation. Biol Blood Marrow Transplant. 2012 Aug; 18(8):1174-81.
Score: 0.027
-
Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 2011 Nov 24; 118(22):5957-64.
Score: 0.026
-
Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs. J Immunother. 2010 Nov-Dec; 33(9):975-82.
Score: 0.025
-
Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. Biol Blood Marrow Transplant. 2009 Dec; 15(12):1513-22.
Score: 0.023
-
Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood. 2007 Dec 15; 110(13):4543-51.
Score: 0.020
-
Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007 Jul; 40(2):125-36.
Score: 0.019
-
Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. Cytotherapy. 2006; 8(2):149-57.
Score: 0.018
-
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005 Feb; 11(2):108-14.
Score: 0.017
-
Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood. 2004 Dec 01; 104(12):3429-36.
Score: 0.016
-
CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood. 2004 Feb 01; 103(3):1140-6.
Score: 0.015
-
Cryofibrinogenemia and skin necrosis in a patient with diffuse large cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant. 2000 Dec; 26(12):1343-5.
Score: 0.012
-
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32.
Score: 0.011